Literature DB >> 25099452

Measuring thrombin generation as a tool for predicting hemostatic potential and transfusion requirements following trauma.

Jessica C Cardenas1, Elaheh Rahbar, Matthew J Pommerening, Lisa A Baer, Nena Matijevic, Bryan A Cotton, John B Holcomb, Charles E Wade.   

Abstract

BACKGROUND: Thrombin is the central coagulation protease that activates clotting proteins, triggers platelet aggregation, and converts fibrinogen to fibrin. Relationships between thrombin generation (TG) and clinical outcomes have not been defined following trauma. We hypothesize that TG is predictive of transfusion requirements and patient outcomes.
METHODS: Plasma was collected from 406 highest-level activation trauma patients upon admission and 29 healthy donors. Standard coagulation tests were performed, and TG was measured by calibrated automated thrombogram. Mann-Whitney U-tests were used to compare healthy versus trauma patients, and subgroup analyses were used to compare hypocoagulable versus nonhypocoagulable patients. Hypocoagulability was determined by area under the receiver operating characteristic curve analysis and was defined as peak TG of less than 250 nM. Multiple logistic regressions were used to assess the ability of TG to predict massive transfusion and mortality.
RESULTS: The median (interquartile range) age was 39 years (28-52 years), with an Injury Severity Score (ISS) of 17 (9-26). The trauma patients had greater TG (peak, 316.2 nM [270.1-355.5 nM]) compared with the healthy controls (124.6 nM [91.1-156.2 nM]), p < 0.001. The overall rate of hypocoagulability was 17%. The patients with peak TG of less than 250 nM were more severely injured (ISS, 25 [13-30] vs. 16 [9-25], p = 0.003); required more transfusions of red blood cells (p = 0.02), plasma (p = 0.003), and platelets (p = 0.006); had fewer hospital-free days (p = 0.001); and had increased mortality (10% vs. 3% at 24 hours, p = 0.006, and 29% vs. 11% at 30 days, p = 0.0004). Peak TG of less than 250 nM was predictive of massive transfusion (odds ratio, 4.18; p = 0.01) and 30-day mortality (odds ratio, 2.78; p = 0.02). Finally, peak TG was inversely correlated with standard coagulation tests.
CONCLUSION: While the physiologic response to injury is to upregulate plasma procoagulant activity, the patients with reduced TG required more transfusions and had poorer outcomes. Measuring TG may provide an exquisitely sensitive tool for detecting disturbances in the enzymatic phases of coagulation in critically injured patients. LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level III.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25099452     DOI: 10.1097/TA.0000000000000348

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  23 in total

1.  Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients.

Authors:  Jessica C Cardenas; Yao-Wei Wang; Jay V Karri; Seenya Vincent; Andrew P Cap; Bryan A Cotton; Charles E Wade
Journal:  Thromb Res       Date:  2020-01-15       Impact factor: 3.944

Review 2.  The Diagnosis and Treatment of Acute Traumatic Bleeding and Coagulopathy.

Authors:  Marc Maegele
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

3.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

4.  Abnormalities of laboratory coagulation tests versus clinically evident coagulopathic bleeding: results from the prehospital resuscitation on helicopters study (PROHS).

Authors:  Ronald Chang; Erin E Fox; Thomas J Greene; Michael D Swartz; Stacia M DeSantis; Deborah M Stein; Eileen M Bulger; Sherry M Melton; Michael D Goodman; Martin A Schreiber; Martin D Zielinski; Terence O'Keeffe; Kenji Inaba; Jeffrey S Tomasek; Jeanette M Podbielski; Savitri Appana; Misung Yi; Pär I Johansson; Hanne H Henriksen; Jakob Stensballe; Jacob Steinmetz; Charles E Wade; John B Holcomb
Journal:  Surgery       Date:  2017-12-27       Impact factor: 3.982

Review 5.  Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage.

Authors:  Nathan J White; Kevin R Ward; Shibani Pati; Geir Strandenes; Andrew P Cap
Journal:  J Trauma Acute Care Surg       Date:  2017-06       Impact factor: 3.313

Review 6.  Trauma-induced coagulopathy: The past, present, and future.

Authors:  Lucy Z Kornblith; Hunter B Moore; Mitchell J Cohen
Journal:  J Thromb Haemost       Date:  2019-05-13       Impact factor: 5.824

7.  Early chemoprophylaxis is associated with decreased venous thromboembolism risk without concomitant increase in intraspinal hematoma expansion after traumatic spinal cord injury.

Authors:  Ronald Chang; Michelle H Scerbo; Karl M Schmitt; Sasha D Adams; Timothy J Choi; Charles E Wade; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2017-12       Impact factor: 3.313

8.  Whole blood thrombin generation is distinct from plasma thrombin generation in healthy volunteers and after severe injury.

Authors:  Julia R Coleman; Ernest E Moore; Jason M Samuels; Joshua J Ryon; Jesse T Nelson; Alexander Olson; Sandi Caus; Matthew G Bartley; Navin G Vigneshwar; Mitchell J Cohen; Anirban Banerjee; Christopher C Silliman; Saulius Butenas
Journal:  Surgery       Date:  2019-09-13       Impact factor: 3.982

9.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2016-04-12       Impact factor: 9.097

Review 10.  Advances in the understanding of trauma-induced coagulopathy.

Authors:  Ronald Chang; Jessica C Cardenas; Charles E Wade; John B Holcomb
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.